NCT06223100

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

An Observational Study on the Efficacy and Safety of the Combination Regimen Based on Eravacycline in the Treatment of Multidrug-resistant Bacterial Infections in Immunocompromised Host Populations.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Sichuan Provincial People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The goal of this observational study is to explore the treatment mode and clinical outcome of patients with immunocompromised who received the combined regimen of eraracycline in the treatment of multidrug-resistant bacterial infections, to evaluate the efficacy and safety of the combined regimen of eravacycline in the treatment of multidrug-resistant bacterial infections in immunocompromised host populations, and to provide data reference for the treatment of immunocompromised populations.

Detailed description

The goal of this observational study is to explore the treatment mode and clinical outcome of patients with immunocompromised who received the combined regimen of eraracycline in the treatment of multidrug-resistant bacterial infections, to evaluate the efficacy and safety of the combined regimen of eravacycline in the treatment of multidrug-resistant bacterial infections in immunocompromised host populations, and to provide data reference for the treatment of immunocompromised populations. The main questions it aims to answer are: * The 30-day all-cause mortality of multi-drug resistant bacterial infections in immunocompromised host populations treated with the combined regimen of eravacycline ; * Evaluate the clinical cure rate and symptom improvement rate of eravacycline treatment. According to the clinical practice (symptoms, signs, imaging, culture and drug sensitivity, etc.), the doctor determines the combined regimen of eravacycline, and the combined drugs are used routinely according to their instructions or clinical diagnosis and treatment.

Conditions

• Immune Dysregulation Disorder

Interventions

Type	Name	Description
DRUG	Eravacycline	There is no other intervention.

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2024-01-25
• Last updated: 2024-01-25

Regulatory

• FDA-regulated drug study